GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Intrinsic Value: Projected FCF

Algorae Pharmaceuticals (ASX:1AI) Intrinsic Value: Projected FCF : A$-0.02 (As of Jun. 08, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-08), Algorae Pharmaceuticals's Intrinsic Value: Projected FCF is A$-0.02. The stock price of Algorae Pharmaceuticals is A$0.0115. Therefore, Algorae Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Algorae Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:

ASX:1AI's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.215
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Algorae Pharmaceuticals Intrinsic Value: Projected FCF Historical Data

The historical data trend for Algorae Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Intrinsic Value: Projected FCF Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.05 -0.05 -0.03 -0.02

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.03 - -0.02 -

Competitive Comparison of Algorae Pharmaceuticals's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Algorae Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Price-to-Projected-FCF falls into.



Algorae Pharmaceuticals Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Algorae Pharmaceuticals's Free Cash Flow(6 year avg) = A$-2.55.

Algorae Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun23)*0.8)/Shares Outstanding (Diluted Average)
=(11.613375984848*-2.5485714285714+3.762*0.8)/1346.990
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (ASX:1AI) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Algorae Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0115/-0.019738764374079
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (ASX:1AI) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines